[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmj4NVl9B7SH1m8l-XzSwdDnRNbYk9INH0GQu3tcY1OU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":66,"rows":73},"National Jewish Health",[4],109,false,17,2,155389,6,73,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Cystic Fibrosis",20,{"name":18,"count":19},"Asthma",16,{"name":21,"count":22},"Atopic Dermatitis",7,{"name":24,"count":25},"COPD",4,{"name":27,"count":25},"Food Allergy",{"name":29,"count":30},"Idiopathic Pulmonary Fibrosis",3,{"name":32,"count":9},"Hypnotic Dependence Among Those With Insomnia",{"name":34,"count":9},"Asthma in Children",[36,41,46,51,56,61],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT02947945","Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study","2018-12","Reslizumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT03010436","Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study","2019-07-25","Benralizumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04598919","Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis","2024-09-15","Saracatinab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06618963","Effect of Omalizumab in the Skin of Food Allergy Patients","2026-09","Omalizumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06262282","Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria","2026-12-31","mycobacteriophage",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06270576","Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma","2028-04","Lipopolysaccharides",[67,68,69,70,71,72],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[74,109,131,153,172,195,220,247,265,292,310,328,352,397,424,442,460,484,513,531,549,567,585,609,634,659,684,709,735,760,786,804,822,845,869,896,919,942,967,992,1017,1040,1066,1091,1115],{"intervention":55,"totalTrials":9,"cells":75},{"EARLY_PHASE1":76,"PHASE1":79,"PHASE2":81,"PHASE3":93,"PHASE4":95,"NA":107},{"trials":77,"activeCount":78},[],0,{"trials":80,"activeCount":78},[],{"trials":82,"activeCount":78},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":78,"conditions":90,"interventions":92},"NCT00851370","Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels","WITHDRAWN",[69],"2011-02","2009-01",[91],"Pulmonary Disease, Chronic Obstructive",[55],{"trials":94,"activeCount":78},[],{"trials":96,"activeCount":106,"soonestReadout":54},[97],{"nctId":52,"briefTitle":53,"status":98,"phases":99,"primaryCompletion":54,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":105},"RECRUITING",[71],"2026-12","2024-10-01",40,[27,104],"Food Allergy in Children",[55],1,{"trials":108,"activeCount":78},[],{"intervention":45,"totalTrials":106,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":125,"PHASE4":127,"NA":129},{"trials":112,"activeCount":78},[],{"trials":114,"activeCount":78},[],{"trials":116,"activeCount":106,"soonestReadout":44},[117],{"nctId":42,"briefTitle":43,"status":118,"phases":119,"primaryCompletion":44,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":124},"ACTIVE_NOT_RECRUITING",[69],"2021-12","2017-04-15",10,[18],[45],{"trials":126,"activeCount":78},[],{"trials":128,"activeCount":78},[],{"trials":130,"activeCount":78},[],{"intervention":50,"totalTrials":106,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":134,"activeCount":78},[],{"trials":136,"activeCount":78},[],{"trials":138,"activeCount":106,"soonestReadout":49},[139],{"nctId":47,"briefTitle":48,"status":118,"phases":140,"primaryCompletion":49,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},[68,69],"2025-06-30","2020-11-12",49,[145],"Idiopathic Pulmonary Fibrosis (IPF)",[50],{"trials":148,"activeCount":78},[],{"trials":150,"activeCount":78},[],{"trials":152,"activeCount":78},[],{"intervention":40,"totalTrials":106,"cells":154},{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":156,"activeCount":78},[],{"trials":158,"activeCount":78},[],{"trials":160,"activeCount":106,"soonestReadout":39},[161],{"nctId":37,"briefTitle":38,"status":98,"phases":162,"primaryCompletion":39,"completion":39,"start":163,"enrollment":122,"conditions":164,"interventions":165},[69],"2017-09-12",[18],[40],{"trials":167,"activeCount":78},[],{"trials":169,"activeCount":78},[],{"trials":171,"activeCount":78},[],{"intervention":65,"totalTrials":106,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":193},{"trials":175,"activeCount":78},[],{"trials":177,"activeCount":106,"soonestReadout":64},[178],{"nctId":62,"briefTitle":63,"status":179,"phases":180,"primaryCompletion":64,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NOT_YET_RECRUITING",[68],"2028-06","2024-04",60,[185,18],"Asthma; Eosinophilic",[65],{"trials":188,"activeCount":78},[],{"trials":190,"activeCount":78},[],{"trials":192,"activeCount":78},[],{"trials":194,"activeCount":78},[],{"intervention":60,"totalTrials":106,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":207},{"trials":198,"activeCount":78},[],{"trials":200,"activeCount":78},[],{"trials":202,"activeCount":78},[],{"trials":204,"activeCount":78},[],{"trials":206,"activeCount":78},[],{"trials":208,"activeCount":106,"soonestReadout":59},[209],{"nctId":57,"briefTitle":58,"status":210,"phases":211,"primaryCompletion":59,"completion":212,"start":213,"enrollment":122,"conditions":214,"interventions":219},"ENROLLING_BY_INVITATION",[],"2028-12-31","2024-02-05",[15,215,216,217,218],"Nontuberculous Mycobacterial Lung Disease","Nontuberculous Mycobacterium Infection","Mycobacterium Infections","Mycobacterium; Pulmonary",[60],{"intervention":221,"totalTrials":106,"cells":222},"Colistin",{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":245},{"trials":224,"activeCount":78},[],{"trials":226,"activeCount":78},[],{"trials":228,"activeCount":78},[],{"trials":230,"activeCount":78},[],{"trials":232,"activeCount":78},[233],{"nctId":234,"briefTitle":235,"status":236,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT02918409","IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy","COMPLETED",[71],"2020-09-10","2021-11-22","2016-08-26",51,[15],[221,244],"Tobramycin",{"trials":246,"activeCount":78},[],{"intervention":244,"totalTrials":106,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":263},{"trials":250,"activeCount":78},[],{"trials":252,"activeCount":78},[],{"trials":254,"activeCount":78},[],{"trials":256,"activeCount":78},[],{"trials":258,"activeCount":78},[259],{"nctId":234,"briefTitle":235,"status":236,"phases":260,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":261,"interventions":262},[71],[15],[221,244],{"trials":264,"activeCount":78},[],{"intervention":266,"totalTrials":106,"cells":267},"Budesonide",{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":290},{"trials":269,"activeCount":78},[],{"trials":271,"activeCount":78},[],{"trials":273,"activeCount":78},[],{"trials":275,"activeCount":78},[],{"trials":277,"activeCount":78},[278],{"nctId":279,"briefTitle":280,"status":236,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":287},"NCT01253473","Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)",[71],"2015-09","2016-01","2012-04",46,[91],[266,288,289],"budesonide\u002Fformoterol","Ipratropium\u002Falbuterol",{"trials":291,"activeCount":78},[],{"intervention":288,"totalTrials":106,"cells":293},{"EARLY_PHASE1":294,"PHASE1":296,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":308},{"trials":295,"activeCount":78},[],{"trials":297,"activeCount":78},[],{"trials":299,"activeCount":78},[],{"trials":301,"activeCount":78},[],{"trials":303,"activeCount":78},[304],{"nctId":279,"briefTitle":280,"status":236,"phases":305,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":306,"interventions":307},[71],[91],[266,288,289],{"trials":309,"activeCount":78},[],{"intervention":289,"totalTrials":106,"cells":311},{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":320,"NA":326},{"trials":313,"activeCount":78},[],{"trials":315,"activeCount":78},[],{"trials":317,"activeCount":78},[],{"trials":319,"activeCount":78},[],{"trials":321,"activeCount":78},[322],{"nctId":279,"briefTitle":280,"status":236,"phases":323,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":324,"interventions":325},[71],[91],[266,288,289],{"trials":327,"activeCount":78},[],{"intervention":329,"totalTrials":106,"cells":330},"Sildenafil 40mg oral",{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":348,"NA":350},{"trials":332,"activeCount":78},[],{"trials":334,"activeCount":78},[],{"trials":336,"activeCount":78},[],{"trials":338,"activeCount":78},[339],{"nctId":340,"briefTitle":341,"status":236,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT04039087","Sildenafil Exercise: Role of PDE5 Inhibition",[69,70],"2024-06-30","2019-09-05",26,[15],[329],{"trials":349,"activeCount":78},[],{"trials":351,"activeCount":78},[],{"intervention":353,"totalTrials":30,"cells":354},"sildenafil",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":356,"activeCount":78},[],{"trials":358,"activeCount":78},[],{"trials":360,"activeCount":78},[361,371,381],{"nctId":362,"briefTitle":363,"status":236,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":369},"NCT01132482","Effects of Sildenafil on CFTR-dependent Ion Transport Activity",[69],"2017-05","2015-10",19,[15],[370],"Sildenafil",{"nctId":372,"briefTitle":373,"status":236,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT02626182","Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF",[68,69],"2018-01-18","2018-01-29","2015-12",14,[15],[353],{"nctId":382,"briefTitle":383,"status":236,"phases":384,"primaryCompletion":385,"completion":386,"start":387,"enrollment":388,"conditions":389,"interventions":390},"NCT00659529","Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease",[68,69],"2012-08","2012-12","2008-08",36,[15],[353],{"trials":392,"activeCount":78},[],{"trials":394,"activeCount":78},[],{"trials":396,"activeCount":78},[],{"intervention":398,"totalTrials":106,"cells":399},"0% Hypnotic Medication Taper",{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":418,"PHASE4":420,"NA":422},{"trials":401,"activeCount":78},[],{"trials":403,"activeCount":78},[],{"trials":405,"activeCount":78},[406],{"nctId":407,"briefTitle":408,"status":236,"phases":409,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT02831894","The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation",[69],"2018-06-30","2019-06-30","2015-11-02",74,[32],[398,416,417],"25% Hypnotic Medication Taper","10% Hypnotic Medication Taper",{"trials":419,"activeCount":78},[],{"trials":421,"activeCount":78},[],{"trials":423,"activeCount":78},[],{"intervention":416,"totalTrials":106,"cells":425},{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":427,"activeCount":78},[],{"trials":429,"activeCount":78},[],{"trials":431,"activeCount":78},[432],{"nctId":407,"briefTitle":408,"status":236,"phases":433,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":434,"interventions":435},[69],[32],[398,416,417],{"trials":437,"activeCount":78},[],{"trials":439,"activeCount":78},[],{"trials":441,"activeCount":78},[],{"intervention":417,"totalTrials":106,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":454,"PHASE4":456,"NA":458},{"trials":445,"activeCount":78},[],{"trials":447,"activeCount":78},[],{"trials":449,"activeCount":78},[450],{"nctId":407,"briefTitle":408,"status":236,"phases":451,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":452,"interventions":453},[69],[32],[398,416,417],{"trials":455,"activeCount":78},[],{"trials":457,"activeCount":78},[],{"trials":459,"activeCount":78},[],{"intervention":461,"totalTrials":106,"cells":462},"digitoxin",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":464,"activeCount":78},[],{"trials":466,"activeCount":78},[],{"trials":468,"activeCount":78},[469],{"nctId":470,"briefTitle":471,"status":236,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":477},"NCT00782288","Phase II Study of Digitoxin to Treat Cystic Fibrosis",[69],"2016-08","2010-08",24,[15],[461,461],{"trials":479,"activeCount":78},[],{"trials":481,"activeCount":78},[],{"trials":483,"activeCount":78},[],{"intervention":485,"totalTrials":106,"cells":486},"amithiozone",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":488,"activeCount":78},[],{"trials":490,"activeCount":78},[],{"trials":492,"activeCount":78},[493],{"nctId":494,"briefTitle":495,"status":236,"phases":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":502},"NCT00004689","Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease",[69],"1998-09","1991-01",50,[501],"Mycobacterium Avium-intracellulare Infection",[485,503,504,505,506],"clarithromycin","ethambutol","rifampin","streptomycin",{"trials":508,"activeCount":78},[],{"trials":510,"activeCount":78},[],{"trials":512,"activeCount":78},[],{"intervention":503,"totalTrials":106,"cells":514},{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":525,"PHASE4":527,"NA":529},{"trials":516,"activeCount":78},[],{"trials":518,"activeCount":78},[],{"trials":520,"activeCount":78},[521],{"nctId":494,"briefTitle":495,"status":236,"phases":522,"completion":497,"start":498,"enrollment":499,"conditions":523,"interventions":524},[69],[501],[485,503,504,505,506],{"trials":526,"activeCount":78},[],{"trials":528,"activeCount":78},[],{"trials":530,"activeCount":78},[],{"intervention":504,"totalTrials":106,"cells":532},{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":534,"activeCount":78},[],{"trials":536,"activeCount":78},[],{"trials":538,"activeCount":78},[539],{"nctId":494,"briefTitle":495,"status":236,"phases":540,"completion":497,"start":498,"enrollment":499,"conditions":541,"interventions":542},[69],[501],[485,503,504,505,506],{"trials":544,"activeCount":78},[],{"trials":546,"activeCount":78},[],{"trials":548,"activeCount":78},[],{"intervention":505,"totalTrials":106,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":552,"activeCount":78},[],{"trials":554,"activeCount":78},[],{"trials":556,"activeCount":78},[557],{"nctId":494,"briefTitle":495,"status":236,"phases":558,"completion":497,"start":498,"enrollment":499,"conditions":559,"interventions":560},[69],[501],[485,503,504,505,506],{"trials":562,"activeCount":78},[],{"trials":564,"activeCount":78},[],{"trials":566,"activeCount":78},[],{"intervention":506,"totalTrials":106,"cells":568},{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":570,"activeCount":78},[],{"trials":572,"activeCount":78},[],{"trials":574,"activeCount":78},[575],{"nctId":494,"briefTitle":495,"status":236,"phases":576,"completion":497,"start":498,"enrollment":499,"conditions":577,"interventions":578},[69],[501],[485,503,504,505,506],{"trials":580,"activeCount":78},[],{"trials":582,"activeCount":78},[],{"trials":584,"activeCount":78},[],{"intervention":586,"totalTrials":106,"cells":587},"Ravicti low dose",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":589,"activeCount":78},[],{"trials":591,"activeCount":78},[],{"trials":593,"activeCount":78},[594],{"nctId":595,"briefTitle":596,"status":597,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":19,"conditions":601,"interventions":602},"NCT02323100","Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)","TERMINATED",[68,69],"2022-03-01","2018-12-02",[15],[586],{"trials":604,"activeCount":78},[],{"trials":606,"activeCount":78},[],{"trials":608,"activeCount":78},[],{"intervention":610,"totalTrials":106,"cells":611},"AZD7624",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":628,"PHASE4":630,"NA":632},{"trials":613,"activeCount":78},[],{"trials":615,"activeCount":78},[],{"trials":617,"activeCount":78},[618],{"nctId":619,"briefTitle":620,"status":236,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":9,"conditions":624,"interventions":626},"NCT02753764","Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma",[69],"2019-02-25","2017-01",[625],"Corticosteroid Resistant (CR) Asthmatics",[610,627],"prednisone",{"trials":629,"activeCount":78},[],{"trials":631,"activeCount":78},[],{"trials":633,"activeCount":78},[],{"intervention":635,"totalTrials":106,"cells":636},"RhDNAse Inhalation Solution",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":638,"activeCount":78},[],{"trials":640,"activeCount":78},[],{"trials":642,"activeCount":78},[643],{"nctId":644,"briefTitle":645,"status":236,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":367,"conditions":650,"interventions":652},"NCT03994380","Use of DNAse in Neutrophilic Asthma",[68,69],"2022-05-31","2022-12-31","2020-02-12",[651],"Neutrophilic Asthma",[635],{"trials":654,"activeCount":78},[],{"trials":656,"activeCount":78},[],{"trials":658,"activeCount":78},[],{"intervention":660,"totalTrials":106,"cells":661},"Mesalamine",{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":663,"activeCount":78},[],{"trials":665,"activeCount":78},[],{"trials":667,"activeCount":78},[668],{"nctId":669,"briefTitle":670,"status":236,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":677},"NCT01088243","Targeting Oxidative Stress in Chronic Beryllium Disease",[68,69],"2015-03","2010-03",18,[676],"Chronic Beryllium Disease",[660],{"trials":679,"activeCount":78},[],{"trials":681,"activeCount":78},[],{"trials":683,"activeCount":78},[],{"intervention":685,"totalTrials":106,"cells":686},"Lovastatin",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":688,"activeCount":78},[],{"trials":690,"activeCount":78},[],{"trials":692,"activeCount":78},[693],{"nctId":694,"briefTitle":695,"status":236,"phases":696,"primaryCompletion":697,"completion":697,"start":698,"enrollment":699,"conditions":700,"interventions":702},"NCT00700921","Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)",[69],"2012-11","2008-04",30,[701],"Chronic Obstructive Pulmonary Disease (COPD)",[685],{"trials":704,"activeCount":78},[],{"trials":706,"activeCount":78},[],{"trials":708,"activeCount":78},[],{"intervention":627,"totalTrials":9,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":712,"activeCount":78},[],{"trials":714,"activeCount":78},[],{"trials":716,"activeCount":78},[717],{"nctId":619,"briefTitle":620,"status":236,"phases":718,"primaryCompletion":622,"completion":622,"start":623,"enrollment":9,"conditions":719,"interventions":720},[69],[625],[610,627],{"trials":722,"activeCount":78},[],{"trials":724,"activeCount":78},[],{"trials":726,"activeCount":78},[727],{"nctId":728,"briefTitle":729,"status":236,"phases":730,"primaryCompletion":731,"completion":731,"start":732,"enrollment":102,"conditions":733,"interventions":734},"NCT00361920","Cell Biology of Steroid Resistant Asthma",[72],"2007-03","2006-08",[18],[627],{"intervention":736,"totalTrials":106,"cells":737},"COVID-19 vaccine",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":739,"activeCount":78},[],{"trials":741,"activeCount":78},[],{"trials":743,"activeCount":78},[],{"trials":745,"activeCount":78},[],{"trials":747,"activeCount":78},[],{"trials":749,"activeCount":78},[750],{"nctId":751,"briefTitle":752,"status":236,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":759},"NCT05313087","COVID-19 Vaccine Response in Chronic Respiratory Conditions",[],"2023-12-30","2021-02-03",360,[758],"SARS-CoV Infection",[736],{"intervention":761,"totalTrials":106,"cells":762},"Beclomethasone dipropionate HFA",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":769,"PHASE4":771,"NA":773},{"trials":764,"activeCount":78},[],{"trials":766,"activeCount":78},[],{"trials":768,"activeCount":78},[],{"trials":770,"activeCount":78},[],{"trials":772,"activeCount":78},[],{"trials":774,"activeCount":78},[775],{"nctId":776,"briefTitle":777,"status":236,"phases":778,"primaryCompletion":88,"completion":88,"start":779,"enrollment":780,"conditions":781,"interventions":783},"NCT00557180","Examining the Link Between Obesity, Inflammation, and Response to Asthma Medications",[],"2007-10",33,[18,782],"Obesity",[761,784,785],"Tiotropium bromide","Salmeterol xinafoate",{"intervention":784,"totalTrials":106,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":794,"PHASE4":796,"NA":798},{"trials":789,"activeCount":78},[],{"trials":791,"activeCount":78},[],{"trials":793,"activeCount":78},[],{"trials":795,"activeCount":78},[],{"trials":797,"activeCount":78},[],{"trials":799,"activeCount":78},[800],{"nctId":776,"briefTitle":777,"status":236,"phases":801,"primaryCompletion":88,"completion":88,"start":779,"enrollment":780,"conditions":802,"interventions":803},[],[18,782],[761,784,785],{"intervention":785,"totalTrials":106,"cells":805},{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":807,"activeCount":78},[],{"trials":809,"activeCount":78},[],{"trials":811,"activeCount":78},[],{"trials":813,"activeCount":78},[],{"trials":815,"activeCount":78},[],{"trials":817,"activeCount":78},[818],{"nctId":776,"briefTitle":777,"status":236,"phases":819,"primaryCompletion":88,"completion":88,"start":779,"enrollment":780,"conditions":820,"interventions":821},[],[18,782],[761,784,785],{"intervention":823,"totalTrials":106,"cells":824},"Triple combination therapy",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":826,"activeCount":78},[],{"trials":828,"activeCount":78},[],{"trials":830,"activeCount":78},[],{"trials":832,"activeCount":78},[],{"trials":834,"activeCount":78},[],{"trials":836,"activeCount":78},[837],{"nctId":838,"briefTitle":839,"status":236,"phases":840,"primaryCompletion":841,"completion":841,"start":344,"enrollment":842,"conditions":843,"interventions":844},"NCT04038710","Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.",[],"2021-02-26",8,[15],[823],{"intervention":846,"totalTrials":106,"cells":847},"Regadenoson",{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":849,"activeCount":78},[],{"trials":851,"activeCount":78},[],{"trials":853,"activeCount":78},[],{"trials":855,"activeCount":78},[],{"trials":857,"activeCount":78},[],{"trials":859,"activeCount":78},[860],{"nctId":861,"briefTitle":862,"status":597,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":122,"conditions":866,"interventions":868},"NCT02220634","Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension",[72],"2017-05-25","2014-08",[867],"Pulmonary Hypertension",[846],{"intervention":870,"totalTrials":106,"cells":871},"systemic corticosteroid or biologic",{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":873,"activeCount":78},[],{"trials":875,"activeCount":78},[],{"trials":877,"activeCount":78},[],{"trials":879,"activeCount":78},[],{"trials":881,"activeCount":78},[],{"trials":883,"activeCount":78},[884],{"nctId":885,"briefTitle":886,"status":887,"phases":888,"primaryCompletion":889,"completion":890,"start":891,"enrollment":892,"conditions":893,"interventions":895},"NCT04283539","Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy","UNKNOWN",[],"2024-06","2025-02","2020-06-01",238,[894],"Cancer",[870],{"intervention":897,"totalTrials":106,"cells":898},"Raltegravir",{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":900,"activeCount":78},[],{"trials":902,"activeCount":78},[],{"trials":904,"activeCount":78},[],{"trials":906,"activeCount":78},[],{"trials":908,"activeCount":78},[],{"trials":910,"activeCount":78},[911],{"nctId":912,"briefTitle":913,"status":236,"phases":914,"primaryCompletion":88,"completion":88,"start":915,"enrollment":699,"conditions":916,"interventions":918},"NCT00738569","Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen",[72],"2008-07",[917],"HIV",[897],{"intervention":920,"totalTrials":106,"cells":921},"Ambrisentan",{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":923,"activeCount":78},[],{"trials":925,"activeCount":78},[],{"trials":927,"activeCount":78},[],{"trials":929,"activeCount":78},[],{"trials":931,"activeCount":78},[],{"trials":933,"activeCount":78},[934],{"nctId":935,"briefTitle":936,"status":597,"phases":937,"primaryCompletion":864,"completion":864,"start":938,"enrollment":22,"conditions":939,"interventions":941},"NCT02169752","Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension",[72],"2012-09",[940],"Pre-Pulmonary Atrial Hypertension",[920],{"intervention":943,"totalTrials":106,"cells":944},"Dog Hair Extract, ALK-Abelló, Inc.",{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":946,"activeCount":78},[],{"trials":948,"activeCount":78},[],{"trials":950,"activeCount":78},[],{"trials":952,"activeCount":78},[],{"trials":954,"activeCount":78},[],{"trials":956,"activeCount":78},[957],{"nctId":958,"briefTitle":959,"status":236,"phases":960,"primaryCompletion":961,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT01343420","Dog Hair Extract Study",[72],"2011-10","2010-11",15,[965],"Potency of Dog Hair Extract",[943],{"intervention":968,"totalTrials":106,"cells":969},"PPV-23",{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":980},{"trials":971,"activeCount":78},[],{"trials":973,"activeCount":78},[],{"trials":975,"activeCount":78},[],{"trials":977,"activeCount":78},[],{"trials":979,"activeCount":78},[],{"trials":981,"activeCount":78},[982],{"nctId":983,"briefTitle":984,"status":887,"phases":985,"primaryCompletion":986,"completion":986,"start":987,"enrollment":988,"conditions":989,"interventions":991},"NCT02726347","Pneumococcal Post-Vaccination Titers",[72],"2018-04","2016-04",140,[990],"Smokers, Elderly, Asthma, COPD, Recurrent Infections",[968],{"intervention":993,"totalTrials":106,"cells":994},"Salmeterol or Salmeterol\u002FFluticasone",{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":996,"activeCount":78},[],{"trials":998,"activeCount":78},[],{"trials":1000,"activeCount":78},[],{"trials":1002,"activeCount":78},[],{"trials":1004,"activeCount":78},[],{"trials":1006,"activeCount":78},[1007],{"nctId":1008,"briefTitle":1009,"status":597,"phases":1010,"primaryCompletion":1011,"completion":1011,"start":1012,"enrollment":16,"conditions":1013,"interventions":1016},"NCT00233051","Evaluating Genes in Sputum to Measure Drug Response in COPD",[72],"2006-06","2003-04",[701,1014,1015],"Emphysema","Chronic Bronchitis",[993],{"intervention":1018,"totalTrials":106,"cells":1019},"HFA-134A Beclomethasone DIpropionate",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1026,"PHASE4":1028,"NA":1030},{"trials":1021,"activeCount":78},[],{"trials":1023,"activeCount":78},[],{"trials":1025,"activeCount":78},[],{"trials":1027,"activeCount":78},[],{"trials":1029,"activeCount":78},[],{"trials":1031,"activeCount":78},[1032],{"nctId":1033,"briefTitle":1034,"status":597,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":16,"conditions":1038,"interventions":1039},"NCT00238082","The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease",[72],"2005-02","1999-11",[24],[1018],{"intervention":1041,"totalTrials":106,"cells":1042},"Xolair",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1044,"activeCount":78},[],{"trials":1046,"activeCount":78},[],{"trials":1048,"activeCount":78},[],{"trials":1050,"activeCount":78},[],{"trials":1052,"activeCount":78},[],{"trials":1054,"activeCount":78},[1055],{"nctId":1056,"briefTitle":1057,"status":887,"phases":1058,"primaryCompletion":1059,"completion":1059,"start":1060,"enrollment":388,"conditions":1061,"interventions":1065},"NCT04060550","Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum",[],"2021-07-31","2020-01-09",[1062,1063,1064],"Atopic Dermatitis With a History of Eczema Herpeticum","Atopic Dermatitis Without a History of Eczema Herpeticum","Health Controls Without Atopy",[1041],{"intervention":1067,"totalTrials":106,"cells":1068},"Hymovis",{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1079},{"trials":1070,"activeCount":78},[],{"trials":1072,"activeCount":78},[],{"trials":1074,"activeCount":78},[],{"trials":1076,"activeCount":78},[],{"trials":1078,"activeCount":78},[],{"trials":1080,"activeCount":78},[1081],{"nctId":1082,"briefTitle":1083,"status":887,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":499,"conditions":1088,"interventions":1090},"NCT04093232","Synovial Fluid Biomarkers Pre and Post Hymovis Knee Injection",[],"2022-01-01","2022-02-01","2019-01-01",[1089],"Knee Osteoarthritis",[1067],{"intervention":1092,"totalTrials":106,"cells":1093},"fluticasone propionate and salmeterol",{"EARLY_PHASE1":1094,"PHASE1":1096,"PHASE2":1098,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1095,"activeCount":78},[],{"trials":1097,"activeCount":78},[],{"trials":1099,"activeCount":78},[],{"trials":1101,"activeCount":78},[],{"trials":1103,"activeCount":78},[],{"trials":1105,"activeCount":78},[1106],{"nctId":1107,"briefTitle":1108,"status":236,"phases":1109,"primaryCompletion":1110,"completion":1110,"start":673,"enrollment":1111,"conditions":1112,"interventions":1113},"NCT01117116","Sub-Sensitivity to Long-Acting Bronchodilators (LABA)",[72],"2013-09",21,[18],[1092,1114],"budesonide and formoterol",{"intervention":1114,"totalTrials":106,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1118,"activeCount":78},[],{"trials":1120,"activeCount":78},[],{"trials":1122,"activeCount":78},[],{"trials":1124,"activeCount":78},[],{"trials":1126,"activeCount":78},[],{"trials":1128,"activeCount":78},[1129],{"nctId":1107,"briefTitle":1108,"status":236,"phases":1130,"primaryCompletion":1110,"completion":1110,"start":673,"enrollment":1111,"conditions":1131,"interventions":1132},[72],[18],[1092,1114]]